Figure 7.

EVs‐3SG mitigate mortality and organ damage in a septicemia model. a) Schematic illustrating the experimental design used for model establishment with a lethal dose of LPS and treatment. b) Survival curve of C57BL/6 mice that received a lethal dose of LPS, n = 6 mice per group. c) Survival curve of BALB/c mice that received a lethal dose of LPS, n = 6 mice per group. d) Schematic illustrating the experimental design used for model establishment with a sublethal dose of LPS and treatment. e) H&E staining of different tissues from mice administered different treatments. EVs‐3SG significantly alleviated lung injury (line 1). In the liver, EVs‐3SG reduced the leakage of inflammatory cells (black arrows) (line 2). In addition, EVs‐3SG mitigated acute kidney injury (line 3). Inflammatory cells (yellow arrows), vacuolated renal tubules (black arrowheads), and the formation of casts (black arrows) were observed. In the spleen, the EVs‐3SG‐treated group had fewer disorganized germinal centers (yellow arrowheads) (line 4). No obvious cardiac changes were observed in the sham, ctrl, EVs‐ctrl, and EVs‐3SG groups (line 5). Scale bar = 50 µm. f) Statistical analysis of the pathological lung injury score, n = 8 mice per group. g) Statistical analysis of the pathological kidney injury score, n = 8 mice per group. h) Statistical analysis of liver inflammatory loci per HPF, n = 8 mice per group. i) Statistical analysis of disorganized germinal centers per HPF, n = 8 mice per group. j) Statistical analysis of inflammatory loci in the heart per HPF, n = 8 mice per group. ****p < 0.0001, ***p < 0.001, **p < 0.01, and *p < 0.05. The data are presented as the means ± SD.